Publications by authors named "Colin Pritchard"

Article Synopsis
  • - Carboxylesterase 2 (CES2) is primarily found in the liver and intestine, playing a significant role in metabolizing various compounds, influencing drug effectiveness, and affecting lipid and glucose metabolism.
  • - The study involved creating knockout mice lacking CES2 genes and transgenic mice with human CES2 to assess the effects of CES2 on drug metabolism and metabolic health.
  • - Findings revealed that while the absence of CES2 led to fatty liver and metabolic issues, introducing human CES2, especially in the intestine, improved these conditions and could potentially address metabolic syndrome challenges.
View Article and Find Full Text PDF
Article Synopsis
  • Innovations in advanced prostate cancer have improved outcomes, but there's still a lack of high-level evidence in clinical management, prompting the 2024 Advanced Prostate Cancer Consensus Conference to survey experts for insights.
  • A panel of 120 international experts developed and voted on 183 consensus questions through a web-based survey prior to the conference, defining consensus as ≥75% agreement.
  • The voting results highlight areas of agreement and disagreement that can guide clinical decisions and future research, with a focus on individualizing treatment based on patient characteristics and encouraging participation in clinical trials.
View Article and Find Full Text PDF

Genomic loss of the transcriptional kinase occurs in ~6% of metastatic castration-resistant prostate cancers (mCRPC) and correlates with poor patient outcomes. Prior studies demonstrate that acute CDK12 loss confers a homologous recombination (HR) deficiency (HRd) phenotype via premature intronic polyadenylation (IPA) of key HR pathway genes, including However, mCRPC patients have not demonstrated benefit from therapies that exploit HRd such as inhibitors of polyADP ribose polymerase (PARP). Based on this discordance, we sought to test the hypothesis that an HRd phenotype is primarily a consequence of acute loss and the effect is greatly diminished in prostate cancers adapted to loss.

View Article and Find Full Text PDF
Article Synopsis
  • - Half of all BRCA1 and BRCA2 gene mutation carriers are male, yet their increased cancer risks—especially for prostate, pancreatic, and breast cancers—are often overlooked compared to females.
  • - Current research shows a growing number of FDA-approved targeted therapies for cancers linked to BRCA1/2 mutations, and there are new clinical trials that focus on male carriers, highlighting the need for better screening and risk-reduction options.
  • - Despite these advancements, fewer males are getting genetic testing compared to females, and healthcare providers need to prioritize offering these tests to men to improve early detection and treatment for male carriers.
View Article and Find Full Text PDF

The Fanconi anemia (FA) repair pathway governs repair of highly genotoxic DNA interstrand crosslinks (ICLs) and relies on translesion synthesis (TLS). TLS is facilitated by REV1 or site-specific monoubiquitination of proliferating cell nuclear antigen (PCNA) (PCNA-Ub) at lysine 164 (K164). A but not mutation renders mammals hypersensitive to ICLs.

View Article and Find Full Text PDF

Objective: We examine whether the rise in neurological death rates over the 21st century are solely explained by the Gompertzian hypothesis.

Study Design: We examine two data-sets. First, Office of National Statistics (ONS, 2022) for nineteen mortality categories in England/Wales, including Alzheimer's, Dementias and Parkinson's Disease.

View Article and Find Full Text PDF
Article Synopsis
  • This document provides guidance on using multigene panels for genetic testing in cancer patients, emphasizing the importance of family history and ethnicity in decision-making.
  • An ASCO Expert Panel reviewed existing guidelines and studies to form their recommendations, identifying significant literature on the topic.
  • Patients should be offered germline genetic testing based on specific criteria, such as family history and identified genetic variants from tumor testing, with recommendations for the minimum and broader panels of genes to include.
View Article and Find Full Text PDF
Article Synopsis
  • Lu-PSMA-617 (LuPSMA) is an effective treatment for metastatic castration-resistant prostate cancer (mCRPC), but the relationship between patients' mutational profiles and clinical outcomes remains unclear.
  • A study analyzed 126 mCRPC patients who received LuPSMA and found that specific genetic mutations significantly impacted the effectiveness of the treatment, with mutations in tumor suppressor genes linked to poorer outcomes.
  • The results indicate that further research is needed to explore how LuPSMA performs in different genetic subgroups to better tailor therapies for prostate cancer patients.
View Article and Find Full Text PDF

(AVPCs) are a subset of metastatic castrate-resistant prostate cancers (mCRPCs) characterized by defects in ≥ two of three of , , and (AVPCm), a profile linked to lineage plasticity, androgen indifference, and platinum sensitivity. Men with mCRPC undergoing biopsies for progression were assessed for AVPCm using immunohistochemistry (IHC), next-generation sequencing (NGS) of solid tumor DNA (stDNA), and NGS of circulating tumor DNA (ctDNA) assays in CLIA-certified labs. Biopsy characteristics, turnaround times, inter-reader concordance, and inter-assay concordance were assessed.

View Article and Find Full Text PDF

In this study, we examined health inequalities and the status of women as evidenced in the patterns of population and mortality statistics in fifteen Muslim-populated countries. Based on WHO data, female-to-male ratios were calculated to determine differential gender ratios of population and mortality, using Western gender patterns as a baseline. The socioeconomic contexts of the analysis were the percentage of women in parliaments data by OECD and the Gross National Income Per Capita PPP by the World Bank.

View Article and Find Full Text PDF

Fanconi anemia (FA) develops due to a mutation in one of the FANC genes that are involved in the repair of interstrand crosslinks (ICLs). FANCG, a member of the FA core complex, is essential for ICL repair. Previous FANCG-deficient mouse models were generated with drug-based selection cassettes in mixed mice backgrounds, leading to a disparity in the interpretation of genotype-related phenotype.

View Article and Find Full Text PDF

Purpose: Among mismatch repair-deficient (MMRd) prostate cancers, loss of MLH1 is relatively uncommon and few cases have been reported in detail.

Methods: Here, we describe the molecular features of two cases of primary prostate cancer with MLH1 loss detected by immunohistochemistry, and in one case, confirmed via transcriptomic profiling.

Results: Both cases were microsatellite stable on standard polymerase chain reaction (PCR)-based microsatellite instability (MSI) testing, but showed evidence of MSI on a newer PCR-based long mononucleotide repeat (LMR) assay and by next-generation sequencing.

View Article and Find Full Text PDF

Mismatch repair (MMR) protein-deficient non-neoplastic colonic crypts and endometrial glands (dMMR crypts and glands) have been reported as a unique marker of underlying Lynch syndrome (LS). However, no large studies have directly compared the frequency of detection in cases with double somatic (DS) MMR mutations. We retrospectively analyzed 42 colonic resection specimens (24 LS and 18 DS) and 20 endometrial specimens (9 LS and 11 DS), including 19 hysterectomies and 1 biopsy for dMMR crypts and glands.

View Article and Find Full Text PDF

Background: Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to making management decisions in daily clinical practise. The 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) addressed some questions in these areas to supplement guidelines that mostly are based on level 1 evidence.

View Article and Find Full Text PDF

Background: Several studies have reported the association of germline BRCA2 (gBRCA2) mutations with poor clinical outcomes in prostate cancer (PCa), but the impact of concurrent somatic events on gBRCA2 carriers survival and disease progression is unknown.

Patients And Methods: To ascertain the role of frequent somatic genomic alterations and histology subtypes in the outcomes of gBRCA2 mutation carriers and non-carriers, we correlated the tumour characteristics and clinical outcomes of 73 gBRCA2 and 127 non-carriers. Fluorescent in-situ hybridisation and next-generation sequencing were used to detect copy number variations in BRCA2, RB1, MYC and PTEN.

View Article and Find Full Text PDF

Purpose Of Review: Personalizing prostate cancer therapy requires germline and tumor molecular tests that predict who will respond to specific treatments and who may not. The review covers molecular testing of DNA damage response pathways, the first biomarker-driven precision target with clinical utility for treatment selection in patients with castration resistant prostate cancer (CRPC).

Recent Findings: Recurrent somatic and germline variants cause deficiency of the mismatch repair (MMR) or homologous recombination (HR) pathways in about a quarter of CRPC patients.

View Article and Find Full Text PDF

The basement membrane (BM) around tumor lobes forms a barrier to prevent cancer cells from invading the surrounding tissue. Although myoepithelial cells are key producers of the healthy mammary epithelium BM, they are nearly absent in mammary tumors. To study the origin and dynamics of the BM, we developed and imaged a laminin beta1-Dendra2 mouse model.

View Article and Find Full Text PDF

The mammalian carboxylesterase 1 (Ces1/CES1) family comprises several enzymes that hydrolyze many xenobiotic chemicals and endogenous lipids. To investigate the pharmacological and physiological roles of Ces1/CES1, we generated cluster knockout ( ) mice, and a hepatic human CES1 transgenic model in the background (TgCES1). mice displayed profoundly decreased conversion of the anticancer prodrug irinotecan to SN-38 in plasma and tissues.

View Article and Find Full Text PDF

Background: Amphicrine prostate carcinoma (AMPC) is a poorly defined subset of prostate cancer in which cells co-express luminal prostate epithelial and neuroendocrine markers. The optimal treatment strategy is unknown. We sought to further characterize the clinical, histomorphologic, and molecular characteristics of AMPC and to identify areas of potential future treatment investigations.

View Article and Find Full Text PDF

Glucose metabolism is dysregulated in Parkinson's disease (PD) causing a shift toward the metabolism of lipids. Carnitine palmitoyl-transferase 1A (CPT1A) regulates the key step in the metabolism of long-chain fatty acids. The aim of this study is to evaluate the effect of downregulating CPT1, either genetically with a Cpt1a P479L mutation or medicinally on PD using chronic rotenone mouse models using C57Bl/6J and Park2 knockout mice.

View Article and Find Full Text PDF
Article Synopsis
  • DNA damage poses a serious threat to genomic stability and can lead to stem cell failure.
  • Cells use DNA damage tolerance (DDT) mechanisms, regulated by PCNA ubiquitination and REV1, to handle this damage during DNA replication.
  • The study shows that disrupting both PCNA-ubiquitination and REV1 leads to severe consequences, including lethality and accumulation of DNA damage in hematopoietic stem cells, highlighting DDT's vital role in sustaining stem cell health and mammalian survival.
View Article and Find Full Text PDF